Anti-SPARCL1 / SPARC-like 1 antibody

Anti-SPARCL1 / SPARC-like 1 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Mouse monoclonal to SPARCL1 / SPARC-like 1

FCM

Human SPARCL1
No cross-reactivity in ELISA with Mouse SDC1

Ecm2 antibody; extracellular matrix protein 2 antibody; hevin antibody; hevin antibody; hevin) antibody; hevin) antibody; mast9 antibody; SC1 antibody; mast9 antibody; PIG33 antibody; proliferation-inducing protein 33 antibody; Sc1 antibody; Sparcl1 antibody; SPARCL1 antibody; SPARC-like 1 (mast9 antibody; SPARC-like 1 (mast9 antibody

Mouse IgG1

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human SPARCL1 (rh SPARCL1; NP_004675.3; Met 1-Phe 664) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

Monoclonal

Aqueous solution containing 0.5% BSA and 0.09% sodium azide

This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

FCM

SPARC-like protein 1 (SPARCL1; also known as SC1, high endothelial venule protein, or hevin) is an extracellular matrix-associated, secreted glycoprotein belonging to the secreted protein acidic and rich in cysteine (SPARC) family of matricellular proteins. It contains three conserved structural domains that are implicated in the regulation of cell adhesion, migration, and proliferation. SPARCL1 is expressed during embryogenesis and tissue remodeling and is especially prominent in brain and vasculature. Its down-regulation in a number of cancers and the possibility of its functional compensation by SPARC has led to recent interest in hevin as a tumor suppressor and regulator of angiogenesis. SPARCL1 has antiadhesive properties, and loss of SPARCL1 expression is associated with increased proliferative activity and cell cycle progression. It is suggested that it may influence multiple cellular processes during distinct stages of brain development and function. In addition, SPARCL1 can influence the function of astroglial cells in the developing and mature central nervous system (CNS).

• Sullivan MM, et al. (2004) Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol. 36(6): 991-6.
• Esposito I, et al. (2007) Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 9(1): 8-17.
• Weimer JM, et al. (2008) A BAC transgenic mouse model to analyze the function of astroglial SPARCL1 (SC1) in the central nervous system. Glia. 56(9): 935-41.